Epigenetic therapy as a novel approach in hepatocellular carcinoma

Anestopoulos, Ioannis; Voulgaridou, Georgia-Persephoni; Georgakilas, Alexandros G.; Franco, Rodrigo; Pappa, Aglaia; Panayiotidis, Mihalis Ι.

doi:10.1016/j.pharmthera.2014.09.005

Cited by 54 publications

(35 citation statements)

References 397 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to genetic changes, it was recently discovered that epigenetic alterations, such as DNA methylation, histone modifications and/or non-coding microRNA patterns, are also involved to hepatocarcinogenesis; thus, novel approaches to developing epigenetic therapy are under active investigation. 44) Unlike genetic events, aberrant signaling in epigenetic regulations are reversible; therefore, targeting the epigenetic machinery of HCC is a strong potential alternative option for single or combinatorial trials with existing targeted agents (e.g. sorafenib) in the treatment of HCC.…”

Section: Future Directionsmentioning

confidence: 99%

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions

Choi

Baik

et al. 2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most lethal neoplasm, causing an estimated 700000 deaths annually. Currently HCC has only one systemic molecular targeted therapy, the multi-kinase inhibitor, sorafenib. The standard-of-care for advanced liver cancer is limited because sorafenib can expand the median life expectancy of patients for only 1 year. Thus there is an urgent need to develop a novel molecular targeted therapy to improve therapeutic outcomes for HCC. HCCs are phenotypically and genetically heterogeneous tumors driven by diverse molecular mechanisms. However, HCCs exhibit certain common traits selected through genetic and epigenetic alterations. The identification of common molecular alterations may provide an opportunity to develop more effective anticancer treatment through targeted therapy. Recent studies in liver cancer biology have revealed a limited number of molecular targets responsible for initiating and maintaining dysregulated cell proliferation, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), c-mesenchymal-epithelial transition factor-1 (c-Met), mammalian target of rapamycin (mTOR) and histone deacetylases (HDACs). New treatments involving inhibitors targeting several of these critical pathways are in development. This review describes the current understanding of target pathways, ongoing clinical trials using HCC-targeted agents, and future directions in the treatment of HCC.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions

Choi

Baik

et al. 2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Actually, the methylation could epigenetically regulate the gene expression by the modification of the histones [20,21]. Histones, including H2A, H2B, H3 and H4, are gathered with DNA as an octamer structure to form the basic unit of chromatin.…”

Section: The Histone Methylation In Hccmentioning

confidence: 99%

Long noncoding RNA, the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma

Yuan

Zhang

et al. 2016

Cancer Letters

View full text Add to dashboard Cite

“…The proliferation inhibition of SAHA-S-S-VE/TPGS NPs was evaluated against HDAC inhibitor sensitive cell lines: MDA-MB-231 (human breast cancer cell), 47 PC-3 (human prostatic cancer), 48 HepG2 (human hepatocellular cancer), 49 and A549 (human lung cancer), 50 compared with free SAHA, SAHA-S-S-VE, SAHA-O-VE, and the conjugate material. The IC 50 values were summarized in Table 2.…”

Section: In Vitro Cytotoxicitymentioning

confidence: 99%

A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy

Han¹,

Wang²,

Wu³

et al. 2016

IJN

View full text Add to dashboard Cite

Epigenetic therapy as a novel approach in hepatocellular carcinoma

Cited by 54 publications

References 397 publications

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions

Long noncoding RNA, the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma

A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy

Contact Info

Product

Resources

About